NASDAQ$COLL
Collegium Pharmaceutical Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Collegium reported strong financial results, driven by the strength of its pain portfolio and growth of Xtampza ER market share, while net income was positively impacted by a one-time non-cash adjustment.
Collegium Pharmaceutical reported strong Q2 results, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza ER market share grew to 31.5% of the oxycodone extended-release market in June 2021. The company updated its full-year 2021 product revenue guidance.
- Xtampza ER market share grew to 31.5% of the oxycodone extended-release market in June 2021.
- Net income for the quarter was $72.8 million, including a one-time non-cash adjustment of $62.6 million.
- Adjusted EBITDA for the quarter was $40.1 million.
- The company updated its full-year 2021 financial guidance for Xtampza ER and Nucynta Franchise revenues.
Headline financials
Revenue & EPS history
Collegium · Revenue · Quarterly
$82.9M
Revenue by segment
Collegium · $82.9M total across 2 segments · Q2 2021
- Nucynta Franchise$49.9M+12.1%60.2%
- Xtampza ER$33M-1.8%39.8%
Forward guidance
The Company updates its full-year 2021 financial guidance for Xtampza ER Revenues and Nucynta Franchise Revenues.
Tailwinds
- Nucynta Franchise Revenues updated from $185.0 to $195.0 million to $195.0 to $205.0 million
- Total Operating Expenses (Including Stock-Based Compensation) reaffirmed at $125.0 to $135.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation) reaffirmed at $170.0 to $180.0 million
- Nucynta Franchise prescriptions grew 0.5% over the first quarter of 2021
- Collegium remains in a strong financial position.
Headwinds
- Collegium is not providing forward-looking guidance for its full-year 2021 U.S. GAAP net income (loss)
- Xtampza ER Revenues updated from $155.0 to $165.0 million to $140.0 to $150.0 million
- Ongoing impact of COVID-19
- Portfolio gross-to-net dynamics
- Adjusting revenue guidance for Xtampza ER and the Nucynta Franchise
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.6%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+2.2%
Avg return
30 days after
61%
28 / 46 earnings
Positive
+31.2%
Q3 2019
Best reaction
-17.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | -2.2% | -8.9% | |
| Q4 2025 | -3.5% | -12.6% | -29.1% | |
| Q3 2025 | +4.4% | +16.5% | +17.8% | |
| Q1 2025 | +5.9% | +6.6% | +10.7% | |
| Q4 2024 | +2.2% | +0.2% | +4.5% | |
| Q3 2024 | -6.8% | -9.0% | -13.1% | |
| Q2 2024 | +2.5% | +5.9% | +7.3% | |
| Q1 2024 | -17.2% | -12.5% | -12.8% | |
| Q4 2023 | +14.5% | +15.8% | +25.1% | |
| Q3 2023 | +4.6% | +10.8% | +23.0% | |
| Q2 2023 | +6.8% | +9.5% | +7.9% | |
| Q1 2023 | +3.6% | +6.4% | -2.2% | |
| Q4 2022 | +1.7% | +0.5% | -10.0% | |
| Q3 2022 | +6.9% | +11.9% | +30.6% | |
| Q2 2022 | +11.4% | +7.2% | -1.0% | |
| Q1 2022 | +1.7% | +10.0% | +15.9% | |
| Q4 2021 | -14.0% | -17.7% | -14.1% | |
| Q3 2021 | -5.3% | +1.0% | -12.5% | |
| Q2 2021 | -17.6% | -23.7% | -19.2% | |
| Q1 2021 | +3.6% | -0.3% | -1.8% | |
| Q4 2020 | -9.6% | -14.1% | -8.8% | |
| Q3 2020 | +2.2% | +4.3% | +1.9% | |
| Q2 2020 | +6.6% | +13.4% | +16.4% | |
| Q1 2020 | +9.4% | +16.2% | +0.3% | |
| Q4 2019 | +5.2% | -1.5% | -27.4% | |
| Q3 2019 | +31.2% | +38.5% | +53.5% | |
| Q2 2019 | +4.0% | +9.6% | +0.9% | |
| Q1 2019 | +5.6% | -2.9% | -18.0% | |
| Q4 2018 | +18.5% | +22.4% | +2.0% | |
| Q3 2018 | -0.4% | +10.8% | +23.1% | |
| Q2 2018 | -5.7% | -2.0% | -15.7% | |
| Q1 2018 | +11.6% | +8.6% | +9.7% | |
| Q4 2017 | +17.9% | +6.3% | -11.9% | |
| Q3 2017 | +25.8% | +44.7% | +75.2% | |
| Q2 2017 | -4.2% | -0.1% | -2.4% | |
| Q1 2017 | +12.5% | +11.5% | +28.0% | |
| Q4 2016 | +7.9% | +7.4% | -34.6% | |
| Q3 2016 | +7.9% | +1.8% | -0.1% | |
| Q2 2016 | -13.1% | -9.7% | -23.8% | |
| Q1 2016 | -3.0% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -10.4% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q1 2014 | -0.8% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro